Zealand Pharma A/S (ZEAL)

Trade ZEAL now with
10/22/2019 6:12:20 AM Zealand Pharma Announces Acquisition Of Encycle Therapeutics
9/24/2019 6:01:47 AM Zealand Pharma Meets Endpoints In Pediatric Phase 3 Trial With Dasiglucagon For Severe Hypoglycemia
9/3/2019 2:08:05 AM Boehringer Ingelheim To Begin Phase 2 Development Of GLP-1/glucagon Dual Agonist BI 456906
8/28/2019 5:07:07 AM Zealand Pharma Appoints Matthew Dallas As New CFO
8/27/2019 4:09:02 AM Zealand Pharma Announces Relocation Into New Corporate Headquarters
6/26/2019 2:26:58 AM Zealand Pharma Doses First Subject In Phase 1 Clinical Trial To Evaluate ZP7570
6/21/2019 3:10:45 AM Zealand Pharma Unveils New Website To Support People With Short Bowel Syndrome
6/13/2019 4:09:11 AM Zealand Pharma Implements New Long-term Incentive Program And Grants New Warrants Under Employee Warrant Program
11/26/2018 10:07:47 AM Zealand Pharma A/S President And CEO Britt Meelby Jensen To Resign
10/4/2018 5:35:28 AM Zealand Pharma Enrolls First Patient In Phase 3 Trial With Glepaglutide For Treatment Of Short Bowel Syndrome
10/1/2018 7:49:04 AM Zealand Pharma A/S Appoints Marino Garcia As SVP Of Corporate & Business Development
9/27/2018 8:56:23 AM Zealand Pharma Begins Phase 3 Trial With Dasiglucagon For Treatment Of Severe Hypoglycemia In Children
9/18/2018 8:15:47 AM Zealand Pharma Says All Primary And Key Secondary Endpoints Achieved In Phase 3 Trial With Dasiglucagon
9/14/2018 3:52:04 AM Zealand Pharma Increases Its Share Capital By A Nominal Amount Of DKK 7,500 Divided Into 7,500 New Shares
7/31/2018 1:51:15 AM Zealand Reports 85% Increase In Soliqua 100/33/ Suliqua Royalty Revenue From Q1 To Q2 Of 2018